This Health Catalyst Insider Increased Their Holding By 42% Last Year
This Health Catalyst Insider Increased Their Holding By 42% Last Year
From what we can see, insiders were net buyers in Health Catalyst, Inc.'s (NASDAQ:HCAT ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.
从我们可以看到,内部人士是净买家在健康催化剂公司S(纳斯达克:HCAT)在过去12个月中。也就是说,内部人士购买股票的数量超过了他们出售股票的数量。
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
尽管就长期投资而言,内幕交易并不是最重要的事情,但从逻辑上讲,你应该关注内部人士是在买入还是卖出股票。
Check out our latest analysis for Health Catalyst
查看我们对Health Catalyst的最新分析
The Last 12 Months Of Insider Transactions At Health Catalyst
Health Catalyst最近12个月的内幕交易
Over the last year, we can see that the biggest insider purchase was by CEO & Director Daniel Burton for US$2.0m worth of shares, at about US$10.14 per share. That means that an insider was happy to buy shares at around the current price of US$10.41. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Health Catalyst share holders is that an insider was buying at near the current price. Daniel Burton was the only individual insider to buy shares in the last twelve months.
在过去的一年里,我们可以看到最大的内部人购买是首席执行官Daniel·伯顿以每股10.14美元的价格购买了价值200万美元的股票。这意味着一位内部人士乐于以目前10.41美元的价格买入股票。这意味着他们过去一直对该公司持乐观态度,尽管他们可能改变了主意。如果有人以远低于当前价格的价格买入股票,总的来说这是一个好兆头,但要记住,他们可能不再看到价值。对于Health Catalyst的股东来说,好消息是一位内部人士以接近当前价格的价格买入。Daniel·伯顿是过去12个月中唯一买入股票的个人内部人士。
Daniel Burton purchased 246.13k shares over the year. The average price per share was US$10.15. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Daniel·伯顿在一年中购买了246.13万股。每股均价为10.15美元。下面的图表显示了过去一年的内幕交易(按公司和个人)。如果你想知道到底是谁卖了,卖了多少钱,什么时候卖的,只需点击下面的图表!
Health Catalyst is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Health Catalyst并不是业内人士唯一买入的股票。对于那些想要找到赢得投资这免费最近有内幕收购的不断增长的公司名单可能就是合适的选择。
Insider Ownership Of Health Catalyst
Health Catalyst的内部人所有权
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 2.6% of Health Catalyst shares, worth about US$16m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
对于一个普通股股东来说,公司内部人士持有多少股份值得一查。我认为,如果内部人士持有该公司大量股份,这是一个好兆头。内部人士拥有Health Catalyst 2.6%的股份,价值约1600万美元。虽然这是一个强大但并不突出的内部人持股水平,但这足以表明管理层和小股东之间的某种一致性。
So What Do The Health Catalyst Insider Transactions Indicate?
那么,Health Catalyst Insider的交易表明了什么?
There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. Insiders do have a stake in Health Catalyst and their transactions don't cause us concern. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 2 warning signs with Health Catalyst and understanding them should be part of your investment process.
过去三个月没有发生任何内幕交易--这并不意味着什么。然而,我们对过去一年交易的分析令人振奋。内部人士确实持有Health Catalyst的股份,他们的交易不会引起我们的担忧。因此,虽然了解内部人士在买入或卖出方面做了什么是有帮助的,但了解一家特定公司面临的风险也是有帮助的。在投资风险方面,我们已经确定了两个警告信号使用Health Catalyst并了解它们应该是您投资过程的一部分。
Of course Health Catalyst may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然了Health Catalyst可能不是最值得购买的股票。所以你可能想看看这个免费汇集了高质量的公司。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前只处理公开市场交易和私下处置直接权益,而不处理衍生工具交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。